{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:08:19Z","timestamp":1786540099342,"version":"build-2736575974"},"reference-count":19,"publisher":"Bentham Science Publishers Ltd.","issue":"4","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDS"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec>\n<jats:title>Introduction:<\/jats:title>\n<jats:p>Hemifacial spasm represents segmental myoclonus of muscles innervated\nby the facial nerve, which is usually and successfully treated with botulinum toxin. Botulinum toxin\n(BTX) acts as an acetylcholine release inhibitor at presynaptic cholinergic junctions and therefore\nis considered contraindicated (or administrable with caution) in patients with neuromuscular\ndisorders like Myasthenia Gravis (MG). Moreover, to date, the association of hemifacial spasm and\nocular MG is extremely rare and only a few cases have been described.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Case Presentation:<\/jats:title>\n<jats:p>We report the case of a 73 years old man with a 3-year history of ocular MG\nwho developed a left hemifacial spasm. The patient underwent hemispasm, treatment with BTX\ntype A (abobotulinum toxin-A, total dose of 50 IU) that resulted in safe and successful 6 months\nre-evaluation.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Our results suggest that in selected cases with concomitant MG and conditions characterized\nby orbicularis oculi spasms or hemispasm, BTX therapy may not be contraindicated and\ncould be given at longer intervals due to prolonged effects.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1574886317666220908094404","type":"journal-article","created":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T05:51:46Z","timestamp":1662961906000},"page":"592-595","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["AChR+ Ocular Myasthenia and Facial Hemispasm: A Case Report of Unusual\nAssociation and Botulinum Toxic Type A Safety and Efficacy"],"prefix":"10.2174","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4037-7630","authenticated-orcid":true,"given":"Stefano","family":"Zoccolella","sequence":"additional","affiliation":[{"name":"Neurology Unit, ASL Bari, San Paolo Hospital, Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo Fabio","family":"Gigante","sequence":"additional","affiliation":[{"name":"Neurology Unit, ASL Bari, San Paolo Hospital, Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Misceo","sequence":"additional","affiliation":[{"name":"Neurology Unit, ASL Bari, San Paolo Hospital, Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"605902","DOI":"10.3389\/fneur.2020.605902","volume":"11","author":"Evoli A.","year":"2020","unstructured":"Evoli A.; Iorio R.; Controversies in ocular myasthenia gravis. Front Neurol 2020,11,605902","journal-title":"Front Neurol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1212\/WNL.58.1.150-a","volume":"58","author":"Roberts M.E.","year":"2002","unstructured":"Roberts M.E.; Steiger M.J.; Hart I.K.; Presentation of myasthenia gravis mimicking blepharospasm. Neurology 2002,58(1),150-151","journal-title":"Neurology"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1001\/archneur.1987.00520220055017","volume":"44","author":"Kurlan R.","year":"1987","unstructured":"Kurlan R.; Jankovic J.; Rubin A.; Patten B.; Griggs R.; Shoulson I.; Coexistent Meige\u2019s syndrome and myasthenia gravis. A relationship between blinking and extraocular muscle fatigue? Arch Neurol 1987,44(10),1057-1060","journal-title":"Arch Neurol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1002\/mds.870020303","volume":"2","author":"Jankovic J.","year":"1987","unstructured":"Jankovic J.; Patten B.M.; Blepharospasm and autoimmune diseases. Mov Disord 1987,2(3),159-163","journal-title":"Mov Disord"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1002\/mds.21558","volume":"22","author":"Hara K.","year":"2007","unstructured":"Hara K.; Matsuda A.; Kitsukawa Y.; Tanaka K.; Nishizawa M.; Tagawa A.; Botulinum toxin treatment for blepharospasm associated with myasthenia gravis. Mov Disord 2007,22(9),1363-1364","journal-title":"Mov Disord"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.toxicon.2020.11.011","volume":"190","author":"Elavarasi A.","year":"2021","unstructured":"Elavarasi A.; Goyal V.; Botulinum neurotoxin in the treatment of hemifacial spasm associated with myasthenia gravis. Toxicon 2021,190,1-2","journal-title":"Toxicon"},{"key":"ref=7","first-page":"500","volume":"43","author":"Tsuda H.","year":"2003","unstructured":"Tsuda H.; Kamei S.; Mizutani T.; Saito N.; Ishikawa H.; Omori K.; Blepharospasm in a patient with thymoma and positive anti-acetylcholine receptor antibody. Rinsho Shinkeigaku 2003,43(8),500-502","journal-title":"Rinsho Shinkeigaku"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1590\/0004-282x20180076","volume":"76","author":"Tang M.","year":"2018","unstructured":"Tang M.; Li W.; Liu P.; He F.; Ji F.; Meng F.; Blepharospasm with elevated anti-acetylcholine receptor antibody titer. Arq Neuropsiquiatr 2018,76(8),522-526","journal-title":"Arq Neuropsiquiatr"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1002\/mds.22931","volume":"25","author":"Voon Y.C.","year":"2010","unstructured":"Voon Y.C.; Yahya W.N.N.W.; Hasan S.; Ibrahim N.M.; Pyridostigmine-induced dystonic blepharospasm in a patient with ocular myasthenia gravis. Mov Disord 2010,25(9),1299-1300","journal-title":"Mov Disord"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1002\/1531-8257(200007)15:4<736::AID-MDS1023>3.0.CO;2-9","volume":"15","author":"Tarsy D.","year":"2000","unstructured":"Tarsy D.; Bhattacharyya N.; Borodic G.; Myasthenia gravis after botulinum toxin a for Meige syndrome. Mov Disord 2000,15(4),736-738","journal-title":"Mov Disord"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/mds.870090319","volume":"9","author":"Emmerson J.","year":"1994","unstructured":"Emmerson J.; Botulinum toxin for spasmodic torticollis in a patient with myasthenia gravis. Mov Disord 1994,9(3),367","journal-title":"Mov Disord"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1212\/01.WNL.0000165997.77985.32","volume":"64","author":"Fasano A.","year":"2005","unstructured":"Fasano A.; Bentivoglio A.R.; Ialongo T.; Soleti F.; Evoli A.; Treatment with botulinum toxin in a patient with myasthenia gravis and cervical dystonia. Neurology 2005,64(12),2155-2156","journal-title":"Neurology"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1590\/S0004-282X1999000400024","volume":"57","author":"Gon&#xE7;alves M.R.R.","year":"1999","unstructured":"Gon&#xE7;alves M.R.R.; Barbosa E.R.; Zambon A.A.; Marchiori P.; Treatment of cervical dystonia with botulinum toxin in a patient with myasthenia gravis. Arq Neuropsiquiatr 1999,57(3A),683-685","journal-title":"Arq Neuropsiquiatr"},{"key":"ref=14","first-page":"527","volume":"32","author":"Funakawa I.","year":"1992","unstructured":"Funakawa I.; Yasuda T.; Katoh H.; Hara K.; Terao A.; A case of bilateral blepharospasm responsive to edrophonium. Rinsho Shinkeigaku 1992,32(5),527-531","journal-title":"Rinsho Shinkeigaku"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"881","DOI":"10.3390\/toxins13120881","volume":"13","author":"Tambasco N.","year":"2021","unstructured":"Tambasco N.; Filidei M.; Nigro P.; Parnetti L.; Simoni S.; Botulinum toxin for the treatment of hemifacial spasm: An update on clinical studies. Toxins 2021,13(12),881","journal-title":"Toxins"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/BF02083302","volume":"18","author":"Berardelli A.","year":"1997","unstructured":"Berardelli A.; Abbruzzese G.; Bertolasi L.; Guidelines for the therapeutic use of botulinum toxin in movement disorders. Ital J Neurol Sci 1997,18(5),261-269","journal-title":"Ital J Neurol Sci"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1136\/jnnp.2003.034702","volume":"75","author":"Jankovic J.","year":"2004","unstructured":"Jankovic J.; Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry 2004,75(7),951-957","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","volume":"52","author":"Wolfe G.I.","year":"1999","unstructured":"Wolfe G.I.; Herbelin L.; Nations S.P.; Foster B.; Bryan W.W.; Barohn R.J.; Myasthenia gravis activities of daily living profile. Neurology 1999,52(7),1487-1489","journal-title":"Neurology"},{"key":"ref=19","unstructured":"Highlights of prescribing information. BOTOX&#xAE; (onabotulinumtoxinA) for injection, for intramuscular, intradetrusor, or intradermal use. Available from:  (Accessed on: July 14, 2020)."}],"container-title":["Current Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1574886317666220908094404","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/208636\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1574886317666220908094404","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,6]],"date-time":"2023-08-06T12:10:38Z","timestamp":1691323838000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/208636\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1574886317666220908094404","relation":{},"ISSN":["1574-8863"],"issn-type":[{"value":"1574-8863","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-03-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-30","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}